Pancreatic Cancer Research

ResearcherUniversity of PaduaActive in the last 2 years

Francesca Tavano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8831-7349; OpenAlex author ID A5028785303. Sources: OpenAlex.

Their work

Papers
47 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
0
Collaborators
114
Papers, trials and grants by year

2012: 3 papers · 2013: 1 paper · 2014: 2 papers · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: 3 papers · 2021: 7 papers · 2022: 1 paper · 2023: 7 papers · 2024: 2 papers · 2025: 4 papers · 2026: 1 paper

Papers 47

  1. Liquid Biopsy Frontiers in Pancreatic Cancer: Insights from Circulating Cell-Free Nucleic Acids. Last author DOI 10.3390/cells15100904↗
  2. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  3. Multi-omic markers of intraductal papillary mucinous neoplasms progression into pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2024.12.005↗
  4. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  5. Could the Microbial Profiling of Normal Pancreatic Tissue from Healthy Organ Donors Contribute to Understanding the Intratumoral Microbiota Signature in Pancre… Co-author DOI 10.3390/microorganisms13020452↗
  6. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  7. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  8. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  9. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  10. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  11. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  12. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  13. Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study. Co-author DOI 10.1186/s10020-023-00600-1↗
  14. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  15. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  16. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  17. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  18. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  19. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  20. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  21. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  22. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  23. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  24. Clinical Significance of Circulating miR-1273g-3p and miR-122-5p in Pancreatic Cancer. Last author DOI 10.3389/fonc.2020.00044↗
  25. Early-Onset Diabetes as Risk Factor for Pancreatic Cancer: miRNA Expression Profiling in Plasma Uncovers a Role for miR-20b-5p, miR-29a, and miR-18a-5p in Diab… Co-author DOI 10.3389/fonc.2020.01567↗
  26. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  27. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  28. High methylation levels of PCDH10 predict poor prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-019-5616-2↗
  29. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  30. Droplet digital PCR quantification of miR-1290 as a circulating biomarker for pancreatic cancer. Co-author DOI 10.1038/s41598-018-34597-z↗
  31. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. Co-author DOI 10.1093/carcin/bgx150↗
  32. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  33. Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Co-author DOI 10.1158/1055-9965.epi-17-0075↗
  34. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  35. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  36. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Last author DOI 10.18632/oncotarget.11041↗
  37. Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients. Co-author DOI 10.18632/oncotarget.7108↗
  38. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  39. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  40. Functional Impact of Autophagy-Related Genes on the Homeostasis and Dynamics of Pancreatic Cancer Cell Lines. Co-author DOI 10.1109/tcbb.2014.2371824↗
  41. SIRT1 and circadian gene expression in pancreatic ductal adenocarcinoma: Effect of starvation. Co-author DOI 10.3109/07420528.2014.1003351↗
  42. A tumour score with multidetector spiral CT for venous infiltration in pancreatic cancer: influence on borderline resectable. Co-author DOI 10.1007/s11547-013-0349-9↗
  43. Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clini… Co-author DOI 10.1186/s12967-014-0248-4↗
  44. Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.1016/j.dld.2012.09.014↗
  45. Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival. Co-author DOI 10.1016/j.ajpath.2012.07.016↗
  46. Correlations among PPARγ, DNMT1, and DNMT3B Expression Levels and Pancreatic Cancer. First author DOI 10.1155/2012/461784↗
  47. Time-Qualified Patterns of Variation of PPARγ, DNMT1, and DNMT3B Expression in Pancreatic Cancer Cell Lines. First author DOI 10.1155/2012/890875↗

Closest collaborators

The 25 strongest of 114 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 10 shared papers, 2013–2025 · strength 0.81
  2. Daniele Campa · 10 shared papers, 2013–2025 · strength 0.81
  3. Tiziana Pia Latiano · 4 shared papers, 2018–2026 · strength 0.74
  4. Andrea Fontana · 9 shared papers, 2012–2023 · strength 0.62
  5. Manuel Gentiluomo · 5 shared papers, 2019–2025 · strength 0.61
  6. Angelo Andriulli · 10 shared papers, 2012–2020 · strength 0.58
  7. Federico Canzian · 9 shared papers, 2013–2023 · strength 0.57
  8. Tommaso Mazza · 5 shared papers, 2015–2025 · strength 0.56
  9. Francesco Perri · 3 shared papers, 2023–2025 · strength 0.50
  10. Raffaele Pezzilli · 8 shared papers, 2012–2023 · strength 0.49
  11. John P. Neoptolemos · 7 shared papers, 2013–2023 · strength 0.49
  12. Pavel Souček · 7 shared papers, 2013–2023 · strength 0.47
  13. Renata Talar‐Wojnarowska · 8 shared papers, 2013–2022 · strength 0.46
  14. Thilo Hackert · 7 shared papers, 2016–2023 · strength 0.45
  15. Fabio F. di Mola · 7 shared papers, 2012–2025 · strength 0.42
  16. Rita Teresa Lawlor · 6 shared papers, 2017–2023 · strength 0.42
  17. Evaristo Maiello · 4 shared papers, 2014–2023 · strength 0.39
  18. Beatrice Mohelníková-Duchoňová · 5 shared papers, 2016–2023 · strength 0.38
  19. Giulia Martina Cavestro · 4 shared papers, 2019–2023 · strength 0.36
  20. Pierluigi Di Sebastiano · 9 shared papers, 2012–2019 · strength 0.36
  21. Maria Gazouli · 6 shared papers, 2013–2022 · strength 0.34
  22. Oliver Strobel · 6 shared papers, 2016–2021 · strength 0.34
  23. Chiara Corradi · 2 shared papers, 2021–2025 · strength 0.33
  24. Pavel Vodička · 5 shared papers, 2013–2023 · strength 0.33
  25. Daniela Basso · 5 shared papers, 2013–2023 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.